Codexis, Inc. today announced the opening of its east coast office, located just outside the metropolitan Philadelphia area in the Great Valley Technology Center located in Malvern, Pennsylvania. The east coast office will facilitate commercial interactions with Codexis’ growing base of pharmaceutical and biotechnology partners who have operations in the region. Codexis now has commercial offices in three locations worldwide, facilitating business development activities and customer interaction. In addition to the company’s Pennsylvania office, Codexis has commercial offices in the United Kingdom and in the San Francisco Bay Area, providing key customer support for Codexis’ partners.

Recently appointed Vice President for Business Development, Kevin Taylor, will coordinate Codexis’ global business development activities from the east coast office. “As Codexis progresses in its evolution towards a product focused company, it is increasingly important to be close to our target markets,” said Mr. Taylor. “With commercial operations located in close proximity to our partners and customers, Codexis is better positioned to attract new business and to be even more responsive to our clients. An east coast office furthermore allows for improved coordination of our expanding North American and European commercial operations.”

About Codexis, Inc.

Codexis, Inc., a majority owned subsidiary of Maxygen, Inc., is a provider of biocatalysis and fermentation processes and products to the life science and fine chemical industries. Codexis’ proprietary MolecularBreeding™ directed molecular evolution technologies allow for the rapid discovery and development of improved or novel processes for the efficient and cost-effective synthesis of valuable chemicals utilizing breakthrough biocatalysts and production strains. Codexis offers its partners R&D services, proprietary biocatalysts and fermentation strains, processes, synthetic and natural products. Codexis has entered into nine strategic alliances in the chemicals field, and has over 19 potential products and processes in its R&D pipeline, with two product candidates in development. In addition, Codexis has five processes now operating at commercial scale, each generating royalty payments. Codexis commenced operations as an independent company in October 2002. MolecularBreeding is a trademark of Maxygen, Inc.

Contact:
Codexis, Inc.
Tassos Gianakakos
Sr. Vice President, Business Development
T. +1-650-298-5423
F. +1-650-298-5449
tassos.gianakakos@codexis.com